Oligometastatic RCC: Challenges and Emerging Therapeutic Strategies

Area of Science:

• Oncology
• Urology

Background:

• Renal-cell carcinoma (RCC) represents approximately 4% of global solid tumors.
• Oligometastatic RCC, defined by fewer than five metastases, is a distinct clinical entity lacking standardized treatment.
• Current treatment algorithms for oligometastatic RCC are not well-established.

Purpose of the Study:

• To review current local and systemic treatment strategies for oligometastatic RCC.
• To identify patient populations who may benefit most from specific treatments.
• To summarize evidence from studies published in the last decade.

Main Methods:

• Narrative review of 26 studies from the past ten years.
• Analysis of local and systemic treatment modalities for oligometastatic RCC.
• Evaluation of treatment efficacy and toxicity profiles.

Main Results:

• Stereotactic ablative radiotherapy (SABR) demonstrated high local control rates and favorable toxicity.
• Systemic therapies exhibited variable efficacy and higher adverse events.
• Limited but feasible evidence exists for radiofrequency ablation, cryoablation, and metastasectomy in select patients.

Conclusions:

• Local therapy, especially SABR, is supported for selected oligometastatic RCC patients.
• Current evidence is largely retrospective and focused on favorable-risk clear cell RCC, limiting generalizability.
• Prospective research is essential to refine patient selection and optimize treatment sequencing.